| Literature DB >> 8212311 |
Abstract
The expression of interleukin 2 (IL-2), induction of its multisubunit receptor and subsequent interplay of this ligand with its receptor are pivotal events in T-cell activation. Our present understanding of the normal IL-2/IL-2 receptor system, and of disorders in this network in disease, opens the possibility for more specific immune intervention. Thomas Waldmann discusses how the clinical application of IL-2, agents that inhibit IL-2 synthesis and action, and anti-IL-2 receptor-directed therapy provide a novel perspective for prevention of allograft rejection and for treatment of graft-versus-host disease, select autoimmune disorders and certain neoplastic diseases.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8212311 DOI： 10.1016/0165-6147(93)90201-t
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN： 0165-6147 Impact factor: 14.819